Recursion, Bayer to wind down fibrosis R&D pact after three years to refocus on cancer

Recursion Pharmaceuticals and Bayer reworked a research pact to focus on oncology instead of fibrosis as the German drugmaking giant homes in on cancer under new CEO Bill Anderson.

Bayer became Recursion’s first Big Pharma partner when the two signed a five-year research deal in 2020 aiming to identify fibrosis…
Click here to view original post


ADVERTISEMENT — Advertise With Biotech Networks